linjc16/ctgov huggingface dataset:
Training Effects in Colonoscopy

Study Overview
=================
Brief Summary
-----------------
Colon cancer is the second most common cause of death among cancer-related deaths in Germany. Precancerous lesions such as adenomas can be detected efficiently by colonoscopy. To provide high quality in colonoscopy several quality parameters have been postulated in the past. The adenoma detection rate (ADR) is one of those parameters. Empirical data suggest that a detection rate of 20% should be demanded. Detection rates are influenced by a multitude of circumstances such as bowel cleanness. The facts that detection rates vary between colonoscopists suggests that leaning effects may also play a role. It is not known how ADR and other quality parameters evolve while trainees improve their skills in colonoscopy. The investigators postulate that a learning curve exists. The investigators therefore plan to evaluate chronologically the findings of trainee colonoscopists. A particular performance in detecting adenomas shall be calculated in relation to the amount of examinations performed.

Official Title
-----------------
The Impact of Training Effects on Quality Indicators in Colonoscopy: a Retrospective Study.

Conditions
-----------------
Adenoma Detection Rate

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: colonoscopy performed at the Technical University Munich, Germany Exclusion Criteria: colonoscopy performed for the purpose of polypectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colonoscopist A<br> | |
| Colonoscopist B<br> | |
| Colonoscopist C<br> | |
| Colonoscopist D<br> | |
| Colonoscopist E<br> | |
| Colonoscopist F<br> | |
| Colonoscopist G<br> | |
| Colonoscopist H<br> | |
| Colonoscopist I<br> | |
| Colonoscopist J<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate | While numbers of investigations rise new detection rates are calculated for each colonoscopist. | every 50 examinations | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Polyp detection rate |  | every 50 examinations | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenoma detection rate, colonoscopy, trainee, learning curve
MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study

Study Overview
=================
Brief Summary
-----------------
Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to observe the selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis in order to be a new target for the treatment of sepsis.

Detailed Description
-----------------
The study is a non-intervention observational study. Purpose of this study is to observe some selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis . The investigators will collect serum samples from patients with sepsis in SICU, RICU and EICU on the 1st、3rd、5th、7th、10th、14th day of 301 Hospital since November 2011 , and then use mirVana PARIS kit extract total RNA and use qRT-PCR detect miRNAS expression in serum which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Official Title
-----------------
MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of sepsis Patients who agree with the study Exclusion Criteria: Aged <18 years; Into the group who died within 24 hours; Agranulocytosis (<0.5 × 109 / L); Combined HIV infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survival Group<br> | |
| Death Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 28days after admited in ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sepsis, miRNA
Dermatological Abnormalities in Beta-thalassemia Major

Study Overview
=================
Brief Summary
-----------------
to study the frequency and pattern of dermatological abnormalities in egyptian childern with beta thalassemia.relationof abnormalities to duration of disease and frequency of transfusion

Detailed Description
-----------------
thalassemia refers to agroup of inherited disease characterized by decreased or absent synthesis of normal globin .skinvdisorders are usually neglected and frequently underdiagnosed among these patients.skin disease specially pruritus and xerosis are observed highly frequently in patients with beta-thalassemia.pityriasis alba is arelatively common skin disorder.the trophic skin changes and leg ulcers occurred after the age of 15 years

Official Title
-----------------
Assessment ofDermatological Abnrmalities in Beta-thalassemia Major in Assiut University Pediatric Hospital

Conditions
-----------------
Beta-Thalassemia

Intervention / Treatment
-----------------
* Device: thalassemia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusio2n Criteria: clinical diagnosis of dermatological abnormalities in thalassemic patient. must be on chelator Exclusion Criteria: patient with other hemolytic anemia. childern with any abnormalities prior to the diagnosis of thalassemi

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with dermatological disorders due to iron overload Iron overload cause dermatological abnormalities | the number of patients who develop any dermatological disorder as a result of iron overload after frequent blood transfusion | one month |
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

Study Overview
=================
Brief Summary
-----------------
Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).

Official Title
-----------------
A Study on Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

Conditions
-----------------
Acute-On-Chronic Liver Failure, Cirrhosis and Chronic Liver Disease

Intervention / Treatment
-----------------
* Diagnostic Test: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of acute-on-chronic liver failure according to Asian-Pacific Association for the Study of the Liver (APASL) diagnostic criteria Exclusion Criteria: Hepatocellular carcinoma(HCC) Portal vein thrombosis Pregnancy Human immunodeficiency virus (HIV) Patients who had received immunomodulator,or cytotoxic/immunosuppressive therapy within at least the preceding 12 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HC,CHB,AD,ACLF<br>HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure. | Diagnostic Test: plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 90 days | 
| incidence of multiorgan failure |  | 90 days | 
| all cause mortality |  | 30 days |
Effects of Proxelan Somministration in Patients With Chronic Prostatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determinate the antinflammatory effects of the Proxelan on a cohort of patients affected by prostatitis'like symptoms and clinical evidence of abacterical prostatistis, trough a significative improvements of pain symptoms according to the NIH-CPSI questionnaire items, spermatozoa motility/concentration variations and the semen cytokines level decrease.

Official Title
-----------------
Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study

Conditions
-----------------
Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Premature Ejaculation

Intervention / Treatment
-----------------
* Drug: Proxelan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - prostatitis like symptoms for at least three months Exclusion Criteria: significant post-voidal residual volume Meares and Stamey test suggestive for bacterial infection neoplasms, urinary stones, antibiotic therapy in the previous three months, irritable bowel syndrome, previous radiotherapic or chemiotherapic treatment, urethral stenosis, neurogenic bladder previous prostatic surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with prostatitis-like symptoms<br>Cohort of patients with CP/CPPS (abacterial prostatitis) | Drug: Proxelan<br>* Administration of one suppository of proxelan once a day for 30 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| National Institutes of Health - Chronic Prostatitis Symptom (NIH-CPS) questionnaires score | Evaluation of pain symptoms trough NIH-CPS questionnaires' pain items (0-6). Values from 0 to 3 normal/slight symptoms; Values from 3 to 6 moderate symptoms; Values over 6 severe symptoms. | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate inflammation, CPS/CPPS, Prostatitis, Proxelan
Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases

Study Overview
=================
Brief Summary
-----------------
The study objectives are to characterize new users of Cyproterone Acetate / Ethinylestradiol (CPA/EE) in 2011/2012 and in 2014 according to demographics, treatment characteristics, previous diagnosis of acne, hirsutism or other hyperandrogenic conditions, previous acne treatment and (concomitant) use of hormonal contraceptives identified in Healthcare Databases in the UK (THIN), the Netherlands (PHARMO) and Italy (HSD).

Official Title
-----------------
Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study population will include all female patients registered in the investigated healthcare databases receiving CPA/EE in 2011 or 2012 (first run) or 2014 (second run), without a prescription of CPA/EE in the year prior to index date. Only patients with recorded history in the database of ≥ 365 days prior to index date will be included in the study. Exclusion Criteria: <365 days recorded history in the database prior to index date a prescription of CPA/EE in the year prior to index date

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Drug Utilisation / Cohort 1<br>New users of CPA/EE in 2011/2012 and in 2014 | Drug: Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics<br>* Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Acne |  | up to 12 months | 
| Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of Hirsutism |  | up to 12 months | 
| Proportion (%) of new users of Diane-35 (or generics) with a previous diagnosis of other Hyperandrogenic Conditions (e.g. androgenic alopecia, seborrhea, polycystic ovary syndrome) |  | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of previous acne treatments (prescription drugs only) of Diane-35 (or generics) users with a previous diagnosis of acne. |  | up to 12 months | 
| Proportion (%) of new Diane-35 (or generics) users, who have concomitant prescriptions of other combined oral contraceptives |  | up to 12 months |
Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy

Study Overview
=================
Brief Summary
-----------------
the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy

Detailed Description
-----------------
eligibility criteria: functional constipation,functional diarrhea，irritable bowel syndrome

Official Title
-----------------
Multicentre Randomized Controlled Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy

Conditions
-----------------
Functional Constipation, Functional Diarrhea

Intervention / Treatment
-----------------
* Drug: Mosapride Citrate tablet
* Device: Low-dose acupuncture
* Device: High-dose acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: function constipation function diarrhea Exclusion Criteria: not function constipation not function diarrhea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Mosapride<br>In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found. | Drug: Mosapride Citrate tablet<br>* Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.<br>* Other names: GASMOTIN;|
| Experimental: Low-dose acupuncture<br>In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants | Device: Low-dose acupuncture<br>* In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants<br>|
| Experimental: High-dose acupuncture<br>In this group,the current was strong enough to reach the patients'tolerance threshold value. | Device: High-dose acupuncture<br>* In this group,the current was strong enough to reach the patients'tolerance threshold value.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acupuncture benefits functional constipation |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acupuncture, functional constipation, functional diarrhea
Psychometric Measurement Properties of the Michigan Hand Questionnaire in Patients After Flexor Tendon Repair

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the psychometric properties of the German Version of the Michigan Hand Questionnaire in patients with flexor tendon injuries, including reliability, validity and interpretability.

Official Title
-----------------
Psychometric Measurement Properties of the German Version of the Michigan Hand Questionnaire in Patients After Flexor Tendon Repair

Conditions
-----------------
Flexor Tendon Rupture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent as documented by signature ≥ 18 years old Understanding of the German language (written and oral) Single and multiple finger injuries Primary flexor tendon injuries in Zone I-V for the fingers and/ or thumb Treated by the hand surgery department at the Inselspital Bern Treated with at least a 4-strand core suture Exclusion Criteria: < 18 years old Inability to follow the procedures of the study, e.g. due to language problems, diagnosed psychological disorders or dementia of the patients Replantation of the injured finger Fracture of the injured finger Primary tendon reconstructions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Michigan Hand Questionnaire (MHQ) | The MHQ is a hand specific questionnaire used to measure the ability in daily function. The total score ranges from 0 to 100, with higher scores indicating better performance. | 6, 13, 13 1/2 and 26 weeks after tendon repair | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disabilities of Shoulder, Arm and Hand Questionnaire | The DASH questionnaire is a region-specific outcome instrument. The patient will rate 30-items about disability or symptoms by rating the degree of difficulty in doing various activities. The scores of all items are used to calculate a score ranging from 0 (no disability) to 100 (most severe disability). The DASH is a region-specific outcome instrument. The patient will rate 30-items about disability or symptoms by rating the degree of difficulty in doing various activities. The scores of all items are used to calculate a score ranging from 0 (no disability) to 100 (most severe disability). | 6, 13 and 26 weeks after tendon repair] |